Article Dans Une Revue Journal of Medicinal Chemistry Année : 2025

Development of Low-Nanomolar Covalent Epoxide Inhibitors of Tubulin Detyrosinating Enzymes VASH1&2

Aline Haetty

Résumé

The development of small molecule inhibitors targeting the set of microtubules' post-translational modifications, also known as the "tubulin code", remains an underexplored area in medicinal chemistry. The recent discovery of the VASH1 and VASH2 enzymes, which are responsible for tubulin detyrosination─a modification associated with neurodegeneration and cancer─prompted us to develop new molecules that inhibit their activity. In this study, we conducted the first QSAR analysis of VASH proteases. Through rational substrate-based design, we identified our lead compound, LV87, as a potent epoxide-based covalent inhibitor of tubulin detyrosination in cellulo. Specificity assessments against other cysteine proteases and incubations with nonspecific nucleophiles demonstrated that LV87 selectively targets VASH1/2. Additionally, safety data, serum, and microsome stability tests support the notion that LV87 is a selective and potent inhibitor of tubulin detyrosination, paving the way for further optimization and applications.

Fichier principal
Vignette du fichier
Revisited_manuscript_Feral_et_al._unmarked.pdf (1.52 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

hal-05328434 , version 1 (30-10-2025)

Licence

Identifiants

Citer

Anthony Feral, Guillaume Marcellin, Yoann Lannay, Camille Hennebert, Yazid Souf, et al.. Development of Low-Nanomolar Covalent Epoxide Inhibitors of Tubulin Detyrosinating Enzymes VASH1&2. Journal of Medicinal Chemistry, 2025, 68 (17), pp.18335-18355. ⟨10.1021/acs.jmedchem.5c00980⟩. ⟨hal-05328434⟩
117 Consultations
167 Téléchargements

Altmetric

Partager

  • More